drugset / Trial / NCT05556967

Identification of Surrogate Blood and/or Urine Biomarker for Immulina TM (Trademark) in Normal Humans

NCT05556967

NaSingle-groupOpen-labelBasic science

Summary

This is a pilot study for identifying plasma and/or urine-derived adherence/surrogate biomarker candidates for verifying Immulina™ ingestion by human volunteers (collected before and after consumption of Immulina™, a natural dietary supplement).

Timeline

Start
2023-08-09
Primary completion
2023-10-19
Completion
2023-10-19

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject spirulina Unknown 800 mg Oral

Indications

No indication recorded.